The role of MEK inhibitors in the treatment of metastatic melanoma.

doi:10.1097/CCO.0000000000000050

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

The role of MEK inhibitors in the treatment of metastatic melanoma.

Current opinion in oncology - 1 Mar 2014

Grimaldi Antonio M, Simeone Ester, Ascierto Paolo A

Abstract excerpt

PURPOSE OF REVIEW: BRAF and NRAS mutations can exert an oncogenic effect and are a target for novel therapeutic strategies. Selective MEK inhibitors inhibit growth and induce cell death in BRAF and NRAS mutated melanoma cell lines. The first MEK inhibitor (trametinib) has recently been approved for the treatment of BRAF-mutated metastatic melanoma not previously treated with BRAF inhibitors and several more are...

Topics

GTP Phosphohydrolases
Humans
MAP Kinase Kinase 1
Melanoma
Membrane Proteins
Mutation
Neoplasm Metastasis
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Pyridones
Pyrimidinones
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 24419498
DOI: 10.1097/CCO.0000000000000050

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics